U.S. markets closed

Aligos Therapeutics, Inc. (ALGS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.47+1.17 (+5.76%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close20.30
Open20.46
Bid20.67 x 1200
Ask21.97 x 900
Day's Range19.85 - 22.08
52 Week Range12.82 - 37.51
Volume42,746
Avg. Volume67,714
Market Cap818.934M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 23, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
      GlobeNewswire

      Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

      - Advanced ALG-010133 and ALG-000184 into the clinic - both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021- Listed on NASDAQ Global Select Market under the symbol ALGS and raised $167.2 million in gross proceeds from the Initial Public Offering (IPO), inclusive of the underwriters’ exercise of their overallotment option- Cash, Cash Equivalents and investments of $243.5 million as of December 31, 2020 SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced its financial results for the fourth quarter and full year 2020 and provided an overview of recent business highlights. "Last year was a transformative year for Aligos,” said Larry Blatt, PhD, MBA, CEO of Aligos. “During 2020, we became both a well-financed public company, via our $167.2 million IPO, as well as a clinical stage company by advancing our first two CHB assets, ALG-010133 and ALG-000184, into the clinic. This year is on track to be similarly impactful for Aligos as we expect to generate important proof of activity data in CHB patients for both ALG-010133 and ALG-000184 as well as advancing two more assets, ALG-020572 and ALG-055009, into the clinic.” “The advancement of these four drug candidates towards and in the clinic this year represents the culmination of three years of hard work by all of our employees,” noted Leo Beigelman, PhD, President of Aligos. “We look forward to seeing the clinical results of these efforts.” Recent Business Highlights Aligos Portfolio of Drug Candidates: ALG-010133 (an S-antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™) molecule that is designed to decrease hepatitis B surface antigen (HBsAg) levels) Single and multiple ascending dose (SAD/MAD) evaluation in healthy volunteers (HV) was completed generating data supportive of commencing dosing in CHB patients.Enrollment of CHB patients is ongoing. The study is evaluating 12 weeks of once weekly subcutaneous ALG-010133/placebo dosing in virologically suppressed CHB patients. Safety and antiviral data from the initial cohort(s) is expected in the second half of 2021. ALG-000184 is a small molecule class II capsid assembly modulator (CAM) that is designed to target hepatitis B virus (HBV) capsid assembly, resulting in decreased HBV DNA/RNA levels, as well as the establishment of covalently closed circular DNA (cccDNA) SAD/MAD evaluation in HV was completed generating data supportive of commencing dosing in CHB patients.Screening in CHB patients has commenced. The study is evaluating 28 days of once daily oral dosing of ALG-000184 or placebo in treatment naïve/currently not treated patients. Safety and antiviral data from the initial cohort(s) expected in the second half of 2021. ALG-020572 (antisense oligonucleotide (ASO) that is designed to decrease HBsAg levels) Advanced into clinical trial application (CTA)-enabling toxicology studies. Planned to begin Phase 1 study in the second half of 2021. ALG-055009 (thyroid hormone beta agonist that is designed to reduce plasma and liver lipid levels in nonalcoholic steatohepatitis (NASH)) Advanced into CTA-enabling toxicology studies. Planned to begin Phase 1 study in the second half of 2021. ALG-125755 (small interfering RNA (siRNA) that is designed to decrease HBsAg levels) Drug candidate identified and advancing into nonclinical studies. CTA-enabling toxicology studies planned for the second half of 2021. Corporate: Expanded the management team with the appointment of Lesley Ann Calhoun as Executive Vice President, Chief Financial Officer in June 2020. Ms. Calhoun is an experienced finance executive with 17+ years in the biopharmaceutical industry as well as an earlier career in U.S. and multinational technology companies and public accounting. Prior to Aligos, she served as Senior Vice President of finance & administration and Chief Accounting Officer at Global Blood Therapeutics, Inc.Awarded €1.8 million Flemish Agency for Innovation and Entrepreneurship (VLAIO) grant to advance chronic hepatitis B research. CHB Related License & Collaboration Agreements: Aligos and Emory University Announce Expanded License Agreement and Ink Collaboration Agreement for CHB (Q2’20) The expanded license includes additional technology developed at Emory and relates to Aligos’ CAM efforts in CHB.The collaboration pertains to the synthesis and evaluation of CAM compounds arising from the additional licensed technology pursuant to a one-year research plan with an option to extend the plan for a second year. Coronavirus Related License & Collaboration Agreements: Aligos Expands Licensing Agreement with Luxna Biotech in Oligonucleotide Technology to Include Novel Coronavirus Targets (Q3’20) The expanded agreement grants Aligos exclusive rights to use Luxna’s technology to target the genomes of certain families of respiratory viruses, including Coronaviridae, which includes SARS-CoV-2, the virus which causes COVID-19. Aligos and KU Leuven Announce a Collaboration and License Agreement for the Development of a Therapeutic Candidate Targeting Coronavirus (Q3’20) The agreement with KU Leuven pertains to the parties’ collaboration to develop coronavirus protease inhibitors as potential therapeutic candidates to address the COVID-19 pandemic and grants to Aligos exclusive, worldwide rights to manufacture and commercialize any such resulting therapeutics. NASH Related License & Collaboration Agreement: Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH (Q4’20) The collaboration relates to the parties’ application of Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a NASH target (and up to one additional target of interest in the cardiometabolic/fibrosis space). Under the agreement, Merck is granted exclusive, worldwide rights to conduct subsequent research, clinical development and commercialization efforts of the oligonucleotides resulting from the collaboration efforts. Financial Results for the Fourth Quarter and Full Year 2020 Cash, cash equivalents and investments totaled $243.5 million on December 31, 2020 compared with $127.7 million on December 31, 2019, reflecting the $167.2 million in gross proceeds from the Company’s initial public offering in October 2020, inclusive of the underwriters’ exercise of their overallotment option. Net losses for the fourth quarter and full year 2020 were $34.4 million and $108.5 million, respectively, or basic and diluted net loss per common share of $1.09 and $10.87, respectively. This compared to net losses of $18.2 million and $52.3 million, respectively, or basic and diluted net loss per common share of $7.27 and $26.04, respectively for the same periods in 2019. Research and development (R&D) expenses were $28.1 million and $79.9 million for the fourth quarter and full year 2020, respectively, compared to $15.0 million and $44.0 million for the same periods in 2019, respectively. The increase in R&D expenses for both comparative periods is primarily attributable to increased expenses related to the Company’s development of ALG-010133 and ALG-000184 clinical trial activities, as well as increases in salaries and employee-related expenses. Total R&D stock-based compensation expense incurred for the three months ended December 31, 2020, was $0.7 million compared with $0.1 million for the same period in 2019. Total R&D stock-based compensation expense incurred in the year ended December 31, 2020, was $1.0 million, compared with $0.5 million for the same period in 2019. General and administrative (G&A) expenses were $6.2 million and $17.9 million for the fourth quarter and full year 2020, respectively, compared to $3.5 million and $10.0 million for the same periods of 2019, respectively. The increase in G&A for both comparative periods is primarily attributable to higher employee-related costs associated with the growth of the Company’s operations and additional professional and consulting services related to being a public company. Total G&A stock-based compensation expense incurred for the three months ended December 31, 2020, was $0.6 million compared with $0.1 million for the same period in 2019. Total G&A stock-based compensation expense incurred in the year ended December 31, 2020, was $1.9 million, compared with $0.3 million for the same period in 2019. About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding Aligos’s expectations in generating proof of activity data in CHB patients for both ALG-010133 and ALG-000184 as well as advancing ALG-020572 and ALG-055009 into the clinic in 2021; expectations in receiving safety and antiviral data from the initial CHB patient cohort(s) in the ALG-010133 study in the second half of 2021; expectations in receiving safety and antiviral data from the initial CHB patient cohort(s) in the ALG-000184 study in the second half of 2021; plans to begin Phase 1 study for ALG-020572 in the second half of 2021; plans to begin Phase 1 study for ALG-055009 in the second half of 2021; and plans to advance ALG-125755 into CTA-enabling toxicology studies in the second half of 2021. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’s clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 23, 2021 and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Aligos Therapeutics, Inc Condensed Consolidated Statements of Operations(In thousands, except share and per share amounts) Three Months Ended Year Ended December 31, December 31, 2020 2019 2020 2019 (Unaudited) (Unaudited) (Unaudited) Operating Expenses: Research and development $28,081 $14,973 $79,890 $44,038 Selling, general and administrative 6,205 3,463 17,944 10,005 Total operating expenses 34,286 18,436 97,834 54,043 Loss from operations (34,286) (18,436) (97,834) (54,043) Interest and other income (expense), net 85 337 (10,548) 1,864 Loss before income tax expense (34,201) (18,099) (108,382) (52,179) Income tax expense (219) (85) (161) (85) Net loss $(34,420) $(18,184) $(108,543) $(52,264) Basic and diluted net loss per common share $(1.09) $(7.27) $(10.87) $(26.04)Weighted-average number of shares used in computing basic and diluted net loss per common share 31,465,208 2,500,501 9,988,191 2,007,173 Aligos Therapeutics, IncCondensed Consolidated Balance Sheets(in thousands) December 31, 2020 December 31, 2019 (Unaudited) Assets Current assets: Cash and cash equivalents$220,383 $69,565Short-term investments 23,130 48,098Prepaid expenses and other current assets 6,504 2,563Total current assets 250,017 120,226Long-term investments - 10,019Other assets 15,285 16,275Total assets$265,302 $146,520 Current liabilities$30,274 $13,818Other liabilities, noncurrent 14,989 15,514Total liabilities 45,263 29,332Total stockholders’ equity 220,039 117,188Total liabilities and stockholders’ equity$265,302 $146,520 Media ContactAmy Jobe, Ph.D.LifeSci Communications+1 315 879 8192ajobe@lifescicomms.com Investor ContactCorey Davis, Ph.D.LifeSci Advisors+1 212 915 2577cdavis@lifesciadvisors.com

    • Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study
      GlobeNewswire

      Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study

      The first drug candidate in Aligos’s chronic hepatitis B portfolio to be administered to CHB patientsSOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has started dosing in the first cohort of chronic hepatitis B (CHB) patients in the ongoing ALG-010133-101 study (NCT04485663). This trial is evaluating ALG-010133, a proprietary oligonucleotide S-antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™) molecule, which was developed to reduce viral S-antigen (or HBsAg) levels in CHB patients. “S-antigen suppresses immune responses and plays a major role in maintaining HBV replication in patients with CHB,” said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. “Our lead STOPS candidate, ALG-010133, has demonstrated potent inhibition of S-antigen levels in preclinical studies. This observation, coupled with the drug’s clinical profile to date, led us to initiate dosing with ALG-010133 in CHB patients to assess its ability to suppress S-antigen levels. It is exciting to have taken the first step in evaluating ALG-010133 in CHB patients. Our goal is to develop a therapeutic regimen that can lead to functional cure for patients living with CHB.” ALG-010133-101 (NCT04485663) is a multi-part umbrella trial that is evaluating the safety, pharmacokinetics and antiviral activity of up to twelve weekly doses of subcutaneously administered ALG-010133 in healthy volunteers (HVs) and virologically suppressed patients with CHB. Seventy-two healthy volunteers have been dosed to date, and preliminary data indicate that ALG-010133 has an acceptable safety and PK profile after as many as three weekly subcutaneous doses. The drug levels achieved at doses evaluated in HVs are expected to result in antiviral activity, thus supporting further evaluation of ALG-010133 in CHB patients. Matthew W. McClure, M.D., Chief Medical Officer of Aligos, added, “This is an exciting next step for Aligos. We have now entered an important phase in the ALG-010133-101 study where we will define the clinical profile of ALG-010133 in our target population, patients with CHB. We expect to begin reporting safety, pharmacokinetic, and antiviral activity data for ALG-010133 from the initial patient cohorts of this study in the second half of 2021.” Professor Ed Gane, MB ChB, Principal Investigator for the ALG-010133-101 study, added, “I believe that drugs that reduce S-antigen levels will play an important role in achieving much higher rates of functional cure than can be achieved with current therapies and look forward to evaluating the potential role that this promising drug candidate may play in future treatment regimens.” Aligos’ STOPS program represents one of several in the company’s CHB portfolio that target different clinically validated mechanisms of action in the hepatitis B virus life cycle. The portfolio also includes capsid assembly modulator (CAM), antisense oligonucleotide (ASO), and small interfering RNA (siRNA) drug candidates. The properties of these candidates indicate that their use in combination could yield potentially best-in-class treatment regimens that may achieve higher rates of functional cure than current standard of care. For each of these drug candidates, Aligos plans to initially establish proof of concept as monotherapy in Phase 1 umbrella trials before evaluating them in combination in subsequent trials. About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding Aligos’s goal to develop a therapeutic regimen that can lead to functional cure for patients living with CHB; expectations that the drug levels achieved at doses evaluated in HVs will result in antiviral activity and thus supporting further evaluation of ALG-010133 in CHB patients; plans to define the clinical profile of ALG-010133 in patients with CHB in its ALG-010133-101 study; expectations to begin reporting safety, pharmacokinetic, and antiviral activity data for ALG-010133 from the initial patient cohorts of the study in the second half of 2021; use of Aligos’ candidates in its CHB portfolio in combination yielding potentially best-in-class treatment regimens that may achieve higher rates of functional cure than current standard of care; plans to initially establish proof of concept as monotherapy in Phase 1 umbrella trials before evaluating its CHB candidates in combination in subsequent trials; belief that drugs which reduce S-antigen levels will play an important role in achieving much higher rates of functional cure than can be achieved with current therapies; and evaluation of the potential role that ALG-010133 may play in future treatment regimens. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’s clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’s prospectus filed with the Securities and Exchange Commission on October 19, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Media ContactAmy Jobe, Ph.D.LifeSci Communications+1 315 879 8192ajobe@lifescicomms.com Investor ContactCorey Davis, Ph.D.LifeSci Advisors+1 212 915 2577cdavis@lifesciadvisors.com

    • Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections
      GlobeNewswire

      Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections

      SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company delivered a presentation on its SARS-CoV-2 3CLpro inhibitor candidate, ALG-097111, at the 28th Conference on Retroviruses and Opportunistic Infections, being held virtually March 6 to March 10, 2021, during the meeting’s Science Spotlight sessions on Saturday, March 6. Aligos performed all research in collaboration with Belgian University KU Leuven, in particular its Centre for Drug Design and Discovery (CD3), and the Rega Institute for Medical Research. “Along with our collaborators at CD3 and the Rega Institute, we are proud to have shown what we believe is the first instance of in vivo evidence of SARS-CoV-2 inhibition with a therapeutic candidate in the class of SARS-CoV-2 3CLpro inhibitor compounds,” said Pierre J.M.B. Raboisson, Pharm.D. Ph.D., Executive Vice President, Head of Small Molecule Medicinal Chemistry and European Site Head at Aligos. “We have also observed highly specific, selective activity in vitro that is consistent with the robust viral inhibition we see in aggressive animal models of infection. These findings represent a significant advance toward a highly targeted therapeutic candidate that is urgently needed as the COVID-19 pandemic persists.” The presentation, titled “The 3CLpro Inhibitor ALG-097111 Potently Inhibits SARS-CoV-2 Replication in Hamsters,” demonstrated that Aligos’ nonclinical SARS-CoV-2 therapeutic candidate, ALG-097111, potently inhibited SARS-CoV-2 replication in vivo in the lungs of SARS-CoV-2-infected hamsters, one of the most severe animal models of SARS-CoV-2 infection available. When ALG-097111 was dosed in hamsters challenged with SARS-CoV-2, the authors observed a robust and significant 3.5 log10 (RNA copies/mg) reduction of the viral RNA copies and 3.7 log10 (TCID50/mg) reduction in the infectious virus titers in the lungs. These results provide the first in vivo validation for the SARS-CoV-2 3-chymotrypsin-like cysteine protease (3CLpro), an essential SARS-CoV-2-encoded enzyme, as a promising therapeutic target in COVID-19. The anti-SARS-CoV-2 activity of ALG-097111 was confirmed in human small airway epithelial cell cultures: when ALG-097111 was added at a concentration of 1µM to the basolateral side of the cultures, the compound significantly reduced viral RNA yield at the apical site of the culture by over 3 log10 RNA copies/mg. ALG-097111 also demonstrated high specificity (IC50 = 7 nM) and selectivity in vitro for the viral protease relative to the similar human protease cathepsin L (IC50 > 10 µM), whose inhibition presents potential safety and efficacy concerns for other 3CLpro inhibitors in development. Aligos CEO Lawrence Blatt, Ph.D., MBA, added, “As the COVID-19 pandemic evolves, new strains of SARS-CoV-2 have emerged that may be resistant to vaccine-mediated immune responses. We therefore see a significant need to develop treatment options that effectively block SARS-CoV-2 replication in patients who either have not been vaccinated or who are infected with vaccine-resistant strains. The demonstration of potent preclinical activity in Aligos’ viral protease inhibitor candidate is an important advancement toward this goal.” About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the advancement of any Aligos SARS-CoV-2 3CLpro inhibitor compound (e.g., ALG-097111) as a targeted therapeutic candidate and the development of treatment options that effectively block SARS-CoV-2 replication in patients who either have not been vaccinated or who are infected with vaccine resistant strains. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’s clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’s prospectus filed with the Securities and Exchange Commission on October 19, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Media ContactAmy Jobe, Ph.D.LifeSci Communications+1 315 879 8192ajobe@lifescicomms.com Investor ContactCorey Davis, Ph.D.LifeSci Advisors+1 212 915 2577cdavis@lifesciadvisors.com